TRAMmoniTTR Study Genetic Screening of an At-risk Population for hATTR and Monitoring of TTR Positive Subjects

Prior treatment

• The participant has undergone chemotherapy for any carcinoma

Age

• The participant is younger than 18 years of age

Other

• Informed consent is not obtained from the participant
• The participant has a diagnosis of alcoholism according to International guidelines
• The participant is not at risk for hATTR

• Informed consent is obtained from the participant
• The participant is 18 years of age or older
• The participant has no diagnosis of alcoholism according to international guidelines
• The participant has not undergone chemotherapy for any carcinoma
  • AND
  • The participant is at risk for hATTR due to two or more the factors listed below:
• cardiomyopathy or polyneuropathy with no obvious etiology atypical Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) or Motor Neuron Disease (MND)
• autonomic dysfunction
• hypertrophic cardiomyopathy or heart failure with preserved ejection fraction Left Ventricular Hypertrophy (LVH)
• bilateral carpal tunnel syndrome
• spinal stenosis or spinal radiculopathy
• gait disorders
• ocular changes involving vitreous opacities
• unexplained weight loss \>5kg
• renal abnormalities
• family history of hATTR
• based on imaging or biopsy suspected for the wild type TTR (ATTR) and not genetically tested for hATTR
  • OR • The participant is diagnosed with hATTR
  • OR
• The participant is a 1st or 2nd degree relative of the TTR positive subject